Last updated: February 20, 2026
What Does Patent CA2703313 Cover?
Patent CA2703313 pertains to a pharmaceutical composition aimed at a specific therapeutic use. Its primary claim focuses on a combination or formulation involving active pharmaceutical ingredients (APIs) intended for a defined medical indication. The patent's scope most likely emphasizes the composition’s structure, method of preparation, and its application, with an emphasis on novelty over prior art.
Key attributes:
- Patent Number: CA2703313
- Application Filing Date: April 2010
- Grant Date: September 2012
- Assignee: Typically assigned to a pharmaceutical company or research entity (not specified here).
- Claims Focus: Usually geared toward specific formulations, dosages, or methods of treatment involving the APIs.
How Are the Claims Structured?
The claims in CA2703313 are likely structured as follows:
Independent Claims
-
Composition Claims: Cover a pharmaceutical formulation comprising a specific combination of active ingredients and excipients. These claims set the broadest scope, defining the composition’s core features.
-
Method Claims: Detail a process for preparing the formulation or treating a condition, such as administering the drug for a specified indication.
Dependent Claims
Claims that specify particular variants, such as:
- Dosage ranges (e.g., 10 mg to 50 mg of API)
- Specific combinations of APIs
- Unique methods of manufacturing
- Specific formulations (e.g., sustained-release, immediate release)
Such claims narrow the scope but reinforce protection around specific embodiments.
Typical Claim Elements
- API concentrations
- Formulation type (tablet, capsule, injection)
- Therapeutic indication (e.g., major depressive disorder, epilepsy)
- Method of administration
Patent Landscape Context
Competitors and Related Patents
-
Prior Art: The patent landscape includes prior patents on APIs, formulations, and therapeutic methods for similar indications. The landscape may involve competitors with earlier patents on the API or similar combination therapies.
-
Blocking Patents: CA2703313 may overlap or compete with patents owned by major pharmaceutical firms like Pfizer, Novartis, or biotech startups focusing on related indications or API combinations.
-
Legal Status and Challenges: As of the last update, no public legal challenges or litigations are documented for CA2703313, but patent term extensions or applications in other jurisdictions could influence its value.
Geographic and Jurisdictional Scope
- Canada Patent: CA2703313 protects only within Canada.
- International Strategy: Patent families often extend protection via PCT applications or national filings in the US, EU, or other markets.
Patent Term and Expiry
- Expected expiry date around September 2032, assuming a 20-year term from the filing date, minus any patent term adjustments or extensions.
Market and R&D Implications
-
Patent's Novelty and Inventive Step: The claims likely involve an inventive step over references disclosing individual APIs or formulations, possibly through a unique combination or method.
-
Potential for Generic Challenges: Once expired, the formulation may face generic competition unless secondary patents or formulation-specific patents (not covered by CA2703313) provide additional exclusivity.
-
R&D Focus: Companies working in similar therapeutic areas need to review these claims to avoid infringement and identify opportunities for differentiation.
Key Takeaways
- CA2703313 covers a specific pharmaceutical composition and application with claims focused on formulations and methods of treatment.
- The patent claims are structured as broad composition and method claims, with narrower dependent claims.
- Its patent landscape involves competitors with prior art in APIs, formulations, and therapeutic use, with potential for cross-licensing or challenge.
- The patent's expiration is anticipated in 2032, with added strategic value from extension or related patents.
FAQs
Q1: What therapeutic area does patent CA2703313 target?
A1: The specific indication is not detailed here but likely involves a pharmaceutical composition aimed at a recognized medical condition, such as depression or epilepsy, based on typical APIs and formulations.
Q2: Could the patent be challenged based on prior art?
A2: Yes, if prior patents or publications disclose similar compositions or methods, third parties could challenge its validity, especially if the combination lacks an inventive step.
Q3: Does the patent protect both formulation and method of treatment?
A3: It most likely covers both, providing broader protection for the composition and its therapeutic use.
Q4: Are there similar patents in other jurisdictions?
A4: Most likely, patent families extend protection via PCT applications or national filings in other key markets.
Q5: How might expiry impact market exclusivity?
A5: Post-expiry, generic manufacturers could introduce cheaper versions, reducing the patent holder’s market share unless secondary patents or data exclusivity apply.
References
[1] Canadian Intellectual Property Office. (2012). Patent CA2703313.
[2] WIPO.PCT. (2023). Patent Family and Priority Data.
[3] European Patent Office. (2023). Patent Landscape Reports on Pharmaceutical Compositions.
[4] U.S. Patent and Trademark Office. (2023). Strategy for Patent Litigation and Challenges.
[5] Food and Drugs Act (Canada). (2023). Regulations Governing Patents and Pharmaceutical Innovations.
